The efficacy and safety of anti-PD-1 antibody toripalimab combined with surufatinib in neoadjuvant treatment of locally advanced thyroid cancer: A phase II study.

被引：0
|
作者：
Chen, Jiaying
Ji, Qinghai
Wang, Yu
Huang, Naisi
Hu, Jiaqian
Wei, Wenjun
Huang, Caiping
Shen, Qiang
Li, Duanshu
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Fudan Univ, Dept Head & Neck Surg, Shanghai Canc Ctr, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6084
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of anti-PD-1/anti-PD-L1 antibody therapy in treatment of advanced gastric cancer or gastroesophageal junction cancer: A meta-analysis
    Yang, Li
    Dong, Xian-Zhe
    Xing, Xiao-Xuan
    Cui, Xiao-Hui
    Li, Lin
    Zhang, Lan
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2020, 12 (11) : 1346 - 1363
  • [22] The efficacy and safety of anlotinib in neoadjuvant treatment in locally advanced thyroid cancer: A single-arm phase II clinical trial.
    Huang, Naisi
    Sun, Guohua
    Wang, Yulong
    Chen, Jiaying
    Guan, Qing
    Lu, Zhongwu
    Xiang, Jun
    Wei, Wenjun
    Ma, Ben
    Ji, Qinghai
    Wang, Yu
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [23] A phase I study of toripalimab, an anti-PD-1 antibody, in patients with refractory malignant solid tumors
    Wei, Xiao-Li
    Ren, Chao
    Wang, Feng-Hua
    Zhang, Yang
    Zhao, Hong-Yun
    Zou, Ben-Yan
    Wang, Zhi-Qiang
    Qiu, Miao-Zhen
    Zhang, Dong-Sheng
    Luo, Hui-Yan
    Wang, Feng
    Yao, Sheng
    Xu, Rui-Hua
    CANCER COMMUNICATIONS, 2020, 40 (08) : 345 - 354
  • [24] The safety and efficacy of donafenib combined with anti-PD-1 antibody as adjuvant therapy for patients (pts) with hepatocellular carcinoma (HCC): Updated results of a phase 2 study.
    Chen, Yiwen
    Shen, Yan
    Zhang, Min
    Wu, Jian
    Gao, Shunliang
    Que, Risheng
    Yu, Jun
    Tang, Xiaofeng
    Bai, Xueli
    Liang, Tingbo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [25] Safety and efficacy of the anti-PD-1 monoclonal antibody dostarlimab in patients with recurrent or advanced dMMR endometrial cancer
    Hanker, L. C.
    Oaknin, A.
    Tinker, A.
    Gilbert, L.
    Samouelian, V
    Mathews, C.
    Brown, J.
    Guo, W.
    Danaee, H.
    Im, E.
    Sabatier, R.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2020, 80 (10) : E220 - E220
  • [26] Safety and efficacy of the anti-PD-1 monoclonal antibody dostarlimab in patients with recurrent or advanced dMMR endometrial cancer
    Oaknin, A.
    Tinker, A. V.
    Gilbert, L.
    Samouelian, V.
    Mathews, C. A.
    Brown, J.
    Guo, W.
    Danaee, H.
    Im, E.
    Sabatier, R.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 6 - 6
  • [27] The efficacy and safety of anti-PD-1/PD-L1 antibodies combined with chemotherapy or CTLA4 antibody as a first-line treatment for advanced lung cancer
    Xu, Xiaoling
    Huang, Zhiyu
    Zheng, Lei
    Fan, Yun
    INTERNATIONAL JOURNAL OF CANCER, 2018, 142 (11) : 2344 - 2354
  • [28] Safety, efficacy, pharmacokinetics of uliledlimab alone or combined with toripalimab in advanced solid tumor: Initial results of a phase I/II study.
    Zhou, Qing
    Wu, Lin
    Cui, Jiuwei
    Jiang, Bo
    Yao, Yu
    Zhang, Jian
    Zhao, Mingfang
    Dong, Xiaorong
    Liu, Anwen
    Ma, Rui
    Du, Yingying
    Wang, Huijuan
    Wang, Buhai
    Hu, Xiaohua
    Pan, Hongming
    Zhang, Haibo
    Zhao, Yiqiang
    Meng, Yuan
    Zhu, Andrew X.
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [29] The efficacy and safety of lenvatinib in neoadjuvant therapy in patients with locally advanced thyroid cancer: A singlearm phase II clinical trial
    Yu, J.
    Wu, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S1147 - S1147
  • [30] Updated safety and efficacy results from the phase I study of either LBL-007 (an anti-LAG-3 antibody) in combination with toripalimab (an anti-PD-1 antibody) or LBL-007 in combination with toripalimab and axitinib in patients with advanced melanoma
    Bai, Xue
    Li, Mei
    Chen, Yu
    Si, Lu
    Chen, Jing
    Pu, Xingxiang
    Cheng, Ying
    Zou, Zhengyun
    Zhao, Shiwei
    Li, Tao
    Cai, Shengli
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345